Santhera Pharmaceuticals Holding AG announced preliminary unaudited revenue results for the second half and full year of 2016. For the period, the company reports net revenues of CHF 19.0 million (+340% year-on-year) from sales of its lead product Raxone(R) for the treatment of Leber's hereditary optic neuropathy (LHON).

Net sales for the second half of 2016 of CHF 11.8 million represent an increase of 64% compared to the first half of 2016 (CHF 7.2 million).

For the year 2016, the company expects a net loss of CHF 33 million to CHF 38 million.

For the year 2017, the company expects net sales of Raxone for the currently approved indication to reach CHF 21 million to CHF 23 million.